| Literature DB >> 27335867 |
Yun Hyung Koog1, Won Young Jung2.
Abstract
Objectives. Our objective was to investigate the time course of the placebo effect of acupuncture on pain and the factors affecting the placebo effect. Methods. Previously we retrieved three-armed randomized acupuncture trials including sham and no-treatment groups which were published until October 2009. We searched electronic databases again to identify additional trials from October 2009 to December 2011. After a screening of trials, fifteen three-armed acupuncture trials for pain were included in the analysis. Standardized mean differences between the sham and no-treatment groups were calculated for placebo effect. We then plotted the magnitude of the placebo effect over time. Results. The placebo effect gradually has increased for 12 weeks with a standardized mean difference of 0.74 (95% CI: 0.54 to 0.94). Then it decreased after 12 weeks as time passed. When the placebo effects were compared for factors including methodological qualities, they were not affected by all factors, except patient blinding. Trials with sufficient patient blinding showed a larger placebo effect at 8 weeks than those with insufficient patient blinding (P = 0.0009). Conclusion. The placebo effect of acupuncture showed a unique pattern, which was affected by insufficient patient blinding.Entities:
Year: 2012 PMID: 27335867 PMCID: PMC4893394 DOI: 10.1155/2013/204108
Source DB: PubMed Journal: ISRN Pain ISSN: 2314-4718
Figure 1Study flow diagram.
Characteristics of included trials.
| Study | Clinical conditions | Number of randomized patients∗ | Allocation concealment | Treatment duration (session) | Sham type |
|---|---|---|---|---|---|
| Scharf et al. [ | Knee osteoarthritis | 709 (367, 342) | Central randomization | 6 weeks (10†) | Superficial needling at nonacupoints |
| Brinkhaus et al. [ | Low back pain | 154 (75, 79) | Centralized telephone randomization | 8 weeks (12) | Superficial needling at nonacupoints |
| Witt et al. [ | Knee osteoarthritis | 150 (76, 74) | Centralized telephone randomization | 8 weeks (12) | Superficial needling at nonacupoints |
| Linde et al. [ | Migraine | 157 (81, 76) | Centralized telephone randomization | 8 weeks (12) | Superficial needling at nonacupoints |
| Melchart et al. [ | Tension-type headache | 138 (63, 75) | Centralized telephone randomization | 8 weeks (12) | Superficial needling at nonacupoints |
| Molsberger et al. [ | Low back pain | 121 (61, 60) | Central telephone randomization | 4 weeks (12) | Superficial needling at nonacupoints |
| Leibing et al. [ | Low back pain | 100 (50, 50) | Unclear | 12 weeks (20) | Superficial needling at nonacupoints |
| Foster et al. [ | Knee osteoarthritis | 235 (119, 116) | Centralized telephone randomization | 3 weeks (6) | Nonpenetrating needles at acupoints |
| Cherkin et al. [ | Low back pain | 323 (162, 161) | Central randomization | 7 weeks (10) | Toothpick at acupoints |
| Kotani et al. [ | Abdominal scar pain | 46 (23, 23) | Sequentially sealed opaque envelopes | 4 weeks (20) | Normal needling at nonpainful points |
| S. H. Lee and B.C. Lee [ | Prostatitis | 26 (13, 13) | Unclear | 6 weeks (12) | Superficial needling at nonacupoints and mock electrical stimulation |
| Helms [ | Primary dysmenorrhea | 22 (11, 11) | Unclear | 12 weeks (9) | Normal needling at nonacupoints |
| Sprott [ | Fibromyalgia | 20 (10, 10) | Unclear | 3 weeks (6) | Disconnected laser instrument |
| Greco et al. [ | Systemic lupus erythematosus | 16 (8, 8) | Sequentially sealed opaque envelopes | 5 weeks (10) | Superficial needling at nonacupoints |
| Suarez-Almazor et al. [ | Knee osteoarthritis | 374 (302, 72) | Sequentially sealed opaque envelopes | 6 weeks (12) | Superficial needling at nonacupoints |
*Values are for total randomized patients (patients in sham and no-treatment groups, resp.).
†This trial provided additional sessions for patients who experienced a pain reduction.
Figure 2Time course of the placebo effect. SMD: standardized mean difference.
Figure 3Time course of the placebo effect based on patient blinding. SMD: standardized mean difference.